Pioneers in Neuroscience
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience.
On June 7, 2019, Biogen completed its acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
For investor inquiries related to the Nightstar Therapeutics acquisition, please contact Biogen Investor Relations at IR@biogen.com.
“Being a pioneer in neuroscience means going where others may not be willing to go. We will find new things. We will be breaking new ground. We will be getting out of our comfort zone.”
“Our goal is to deliver innovative therapies for patients and invest in the areas of highest return to deliver long-term value to our stockholders.”
Tennille works in our Patient Services group in Research Triangle Park in North Carolina.